Module 2: Treating challenging RRMM patient subgroups
Learning Objective: To know how to manage challenges in treating certain RRMM patient subgroups
Disclosures of the participating experts are provided here.
Disclaimer: The purpose of this e-learning is to provide you as an HCP with relevant information on the basis of which you can draw your own conclusions. This information is not intended to provide recommendations regarding indications, dosages, or other statements not listed in the Summary of Product Characteristics (smpc) of the products concerned or not listed in the local applicable guidelines for multiple myeloma. Please consult this page for all Summary of Product Characteristics.
All tables and graphs in this e-learning are based on scientific data from peer-reviewed articles; the original graphs or tables may be redesigned to match the style and colors of the e-learning without changing the data.
Accreditation for this e-learning has been granted for 3 points by:
European Accreditation Council for Continuing Medical Education (EACCME)
Obtain CME points
To obtain CME points, you must answer at least 70% of the questions in the final test correctly. If you have a lower score, you can retake the final test twice more. You can pause the e-learning and then resume where you paused.
Throughout the e-learning challenging clinical cases from daily practice are being presented by the International Expert Panel.